| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Estrogen receptor
Endoxifen E-isomer HCl acts as a selective estrogen receptor modulator (SERM), competitively binding to estrogen receptors to block estrogen signaling. It is a tamoxifen metabolite with a much higher potency for the estrogen receptor than its parent drug, tamoxifen. By inhibiting the proliferation of estrogen-dependent breast cancer cells, it exerts its antiestrogenic effects. |
|---|---|
| ln Vitro |
Endoxifen E-isomer (1-1000 nM; 12 h) inhibits PGR gene expression in E2-induced MCF-7 cells[2].
In vitro, Endoxifen E-isomer HCl is a potent SERM that competitively binds estrogen receptors to block estrogen signaling and inhibit the proliferation of estrogen-dependent breast cancer cells. As an active metabolite of tamoxifen, it has a much higher potency for the estrogen receptor than its parent drug. Its antiestrogenic effects have been demonstrated in various cell-based assays. |
| ln Vivo |
In vivo, Endoxifen E-isomer HCl, as an active tamoxifen metabolite, would be expected to contribute to the therapeutic effects of tamoxifen in estrogen-dependent breast cancer. However, as the E-isomer, it is considered the main impurity in the Z-isomer原料, and its specific contribution to the overall therapeutic effect is less prominent than the Z-isomer. It is primarily used as a reference standard for analytical method development and quality control.
|
| Enzyme Assay |
Non-cellular receptor binding assays for Endoxifen E-isomer HCl involve competitive radioligand binding displacement studies using estrogen receptor (ERα and ERβ) preparations. The receptor is incubated with a radiolabeled estradiol ligand and varying concentrations of Endoxifen E-isomer HCl. Following incubation and filtration, bound radioactivity is measured by scintillation counting. IC₅₀ values are determined from displacement curves and converted to Ki values.
|
| Cell Assay |
In vitro cellular assays for Endoxifen E-isomer HCl involve treating estrogen receptor-positive breast cancer cell lines (e.g., MCF-7) with the compound and measuring its effects on cell proliferation. Cells are treated with varying concentrations of Endoxifen E-isomer HCl for 72 hours, and cell viability is measured using MTT or CellTiter-Glo® assays. The compound's ability to inhibit estrogen-stimulated cell growth is assessed in the presence of estradiol.
|
| Animal Protocol |
In vivo animal experiments for Endoxifen E-isomer HCl are not typically conducted, as it is an impurity and reference standard rather than a therapeutic compound. It is used in analytical method development and quality control applications for tamoxifen and its metabolites.
|
| ADME/Pharmacokinetics |
Endoxifen E-isomer HCl has a molecular weight of 409.95 and a molecular formula of C₂₅H₂₈ClNO₂. It is a white to off-white solid powder with a purity of ≥98%. The compound is soluble in DMSO (~81 mg/mL) and ethanol (~81 mg/mL). For storage, the powder should be kept at -20°C for up to 3 years or at 4°C for up to 2 years; stock solutions can be stored at -80°C for 6 months or at -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Endoxifen E-isomer HCl is a research compound for laboratory use only and is not intended for human therapeutic or diagnostic use. Standard laboratory safety precautions should be followed when handling the compound. It may cause skin, eye, and respiratory irritation. Appropriate personal protective equipment should be used. As a SERM, it may have effects on estrogen-sensitive tissues.
|
| References |
|
| Additional Infomation |
Endoxifen E-isomer HCl (E-Endoxifen HCl; CAS 1197194-61-8) is the E-isomer of endoxifen, a potent active metabolite of tamoxifen and a selective estrogen receptor modulator (SERM). It is the main impurity in Endoxifen Z-isomer原料 and exhibits antiestrogenic effects. It is primarily used as a reference standard for analytical method development and quality control in tamoxifen research.
|
| Molecular Formula |
C25H28CLNO2
|
|---|---|
| Molecular Weight |
409.954
|
| Exact Mass |
409.18
|
| Elemental Analysis |
C, 73.25; H, 6.88; Cl, 8.65; N, 3.42; O, 7.81
|
| CAS # |
1197194-61-8
|
| Related CAS # |
Endoxifen (Z-isomer);112093-28-4;Endoxifen Z-isomer hydrochloride;1032008-74-4;Endoxifen hydrochloride;1197194-41-4;Endoxifen (E-isomer);114828-90-9;Endoxifen;110025-28-0
|
| PubChem CID |
91885447
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
467
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.O(CCNC)C1C=CC(=CC=1)/C(/C1C=CC(=CC=1)O)=C(/C1C=CC=CC=1)\CC
|
| InChi Key |
RPFIMPDXTABYCN-QREUMGABSA-N
|
| InChi Code |
InChI=1S/C25H27NO2.ClH/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2;/h4-16,26-27H,3,17-18H2,1-2H3;1H/b25-24+;
|
| Chemical Name |
4-[(E)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;hydrochloride
|
| Synonyms |
Endoxifen E-isomer HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~81 mg/mL (197.6 mM)
Ethanol: ~81 mg/mL (197.6 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4393 mL | 12.1966 mL | 24.3932 mL | |
| 5 mM | 0.4879 mL | 2.4393 mL | 4.8786 mL | |
| 10 mM | 0.2439 mL | 1.2197 mL | 2.4393 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
